Tue, Jan 27, 2015, 3:32 PM EST - U.S. Markets close in 28 mins.


% | $
Quotes you view appear here for quick access.

ALLIQUA, INC. Message Board

gmeabrk 5 posts  |  Last Activity: Nov 20, 2014 3:31 PM Member since: Mar 19, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Question for GME

    by bryan.paul23 Nov 19, 2014 12:30 PM
    gmeabrk gmeabrk Nov 20, 2014 3:31 PM Flag

    For what it's worth, I have no problem envisioning a 5 bagger from here. This is wound care and not cancer care. If this were a conceptual cancer drug company with zero sales and a partner in CELG, this would be trading with a stratospheric valuation, but alas, their stock in trade is wound care and infection mitigation.
    I say 400 million valuation is not unbreasonable because I continually remind myself of their lidocane patch which is clinically better and more user friendly than Lidoderm from Enzo pharma which has sales in excess of 1 billion annually. ALQA also have a functioning FDA approved manufacturing facility so it''s not like they're coming to the party without any presents... I think that it will be an interesting year for ALQA in 2015. Of course, this stock has proven me wrong on many occasions. I don't think so this time. I say parabolic if the market stays strong.

  • Perhaps now it'll start to get interesting. I've never seen a company so cleanly do the things that it's said that it's going to do. Eventually someone's going to start believing in these guys.

  • gmeabrk gmeabrk Oct 29, 2014 3:19 PM Flag

    I don't think that they'll have to if they get this billing code. I think that this will set up a buy of the company by Celg. Biovance has to be a lot more valuable than the paltry valuation of ALQA presently. I also think it's significant that ALQA owns an FDA approved pharmaceutical plant. That's got to be worth something in the whole scheme of things.

  • gmeabrk gmeabrk Oct 29, 2014 10:38 AM Flag

    The way I view this, if they get a billing code, this is off to the races. I remember liking this a year ago because they devised a better, faster working lidocaine patch. Enzo does over a billion in Lidoderm sales and this can't be overlooked by Celgene.

  • It is a binary event. Biovance is more expensive because it is a far better product and they have to make sure that there will be reimbursement for it's use. It is not a "Me Too" product and my bet is that with that abstract about healing second degree burns in half the time, the case can probably be made that money is saved by lessening the chance of infection. But I'm not a doctor, I only play one on Yahoo Message Boards. What do I know?
    In this day and age of non innovative products that simply piggyback off other products, Biovance is a clearly superior product, and I hate to think we've gotten to the point with Obamacare that the edict is out that "we don't want to spend extra"

4.99+0.03(+0.60%)3:16 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.